Literature DB >> 16243311

Enhanced response of pig coronary arteries to endothelin-1 after ischemia-reperfusion. Role of endothelin receptors, nitric oxide and prostanoids.

Belén Climent1, Nuria Fernández, Elena Sanz, Ana Sánchez, Luis Monge, Angel Luis García-Villalón, Godofredo Diéguez.   

Abstract

To analyse the coronary effects of endothelin-1 after ischemia-reperfusion, the left anterior descending coronary artery of anesthetized pigs was subjected to 30-min occlusion followed by 60-min reperfusion. Then, rings distal (ischemic arteries) and proximal (control arteries) to the occlusion were taken from this artery and prepared for isometric tension recording. The sensitivity of the contraction in response to endothelin-1 (3 x 10(-10)-3 x 10(-7) M) and the endothelin ET(B) receptor agonist IRL-1620 (3 x 10(-10)-3 x 10(-7) M) was greater in ischemic vessels. The endothelin ET(A) receptor antagonist BQ-123 (10(-7)-3 x 10(-6) M) decreased the sensitivity of the response to endothelin-1 similarly in ischemic and control arteries. The endothelin ET(B) receptor antagonist BQ-788 (10(-6) M), endothelium removal or the inhibitor of nitric oxide synthesis N(omega)-nitro-L-arginine methyl ester (L-NAME 10(-4) M) potentiated the response to endothelin-1 and IRL-1620 in control arteries only. The cyclooxygenase inhibitor meclofenamate (10(-5) M) augmented the maximal response to endothelin-1 in control arteries, and reduced it in ischemic arteries. In precontracted arteries, IRL-1620 (3 x 10(-11)-3 x 10(-10) M) relaxed control but not ischemic arteries, and L-NAME or meclofenamate abolished this relaxation. Therefore, ischemia-reperfusion increases the coronary vasoconstriction in response to endothelin-1 probably due to impairment of endothelin ET(B) receptor-induced release of nitric oxide and prostacyclin, augmentation of the contractile response to activation of endothelin ET(B) receptors, and increased release of vasoconstrictor prostanoids.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16243311     DOI: 10.1016/j.ejphar.2005.09.002

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  The lung endothelin system: a potent therapeutic target with bosentan for the amelioration of lung alterations in a rat model of diabetes mellitus.

Authors:  A Cayir; R A Ugan; A Albayrak; D Kose; E Akpinar; Y Cayir; H T Atmaca; Z Bayraktutan; M Kara
Journal:  J Endocrinol Invest       Date:  2015-04-07       Impact factor: 4.256

Review 2.  Working under pressure: coronary arteries and the endothelin system.

Authors:  Albert Nguyen; Nathalie Thorin-Trescases; Eric Thorin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-03-17       Impact factor: 3.619

Review 3.  The cardiovascular physiology and pharmacology of endothelin-1.

Authors:  Eric Thorin; Martine Clozel
Journal:  Adv Pharmacol       Date:  2010

Review 4.  Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease.

Authors:  Marc Q Mazzuca; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2012-03-30       Impact factor: 5.858

Review 5.  Endothelium-derived endothelin-1.

Authors:  Eric Thorin; David J Webb
Journal:  Pflugers Arch       Date:  2009-12-05       Impact factor: 3.657

6.  Heart ischaemia-reperfusion induces local up-regulation of vasoconstrictor endothelin ETB receptors in rat coronary arteries downstream of occlusion.

Authors:  G F Skovsted; L S Kruse; R Larsen; A F Pedersen; S Trautner; M Sheykhzade; L Edvinsson
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

7.  Non-endothelial endothelin counteracts hypoxic vasodilation in porcine large coronary arteries.

Authors:  Elise R Hedegaard; Edgaras Stankevicius; Ulf Simonsen; Ole Fröbert
Journal:  BMC Physiol       Date:  2011-05-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.